Caris Life Sciences Announces Participation in the 18th Annual Morgan Stanley Global Healthcare Conference

IRVING, Texas, Sept. 9, 2020 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian J. Brille, Vice Chairman of the Company, will participate in a fireside chat at the 18(th) Annual Morgan Stanley Global Healthcare Conference Thursday, Sept. 17, 2020, at 9:30 a.m. Eastern time.

Mr. Brille will provide an overview of Caris' business, along with its suite of market-leading molecular profiling offerings, and discuss recent corporate growth initiatives that position Caris to further extend its leadership reach in the market. Thomas Parker, Senior Vice President and Chief Financial Officer at Caris, will be available for Q&A.

Attendees who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Morgan Stanley representative.

About Caris Life Sciences
Caris Life Sciences(®) is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome((TM)) whole exome sequencing with 22,000 DNA genes, and MI Transcriptome((TM)) whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.

Caris is also advancing precision medicine with Caris MAI((TM)) (Molecular Artificial Intelligence) that combines its innovative service offerings, Caris Molecular Intelligence(®) with its proprietary artificial intelligence analytics engine, DEAN((TM)), to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Caris Pharmatech is changing the paradigm and streamlines the clinical trial process by assisting biopharma companies with accessing research-ready oncology sites for clinical trials. With over 200 research sites within the Caris Pharmatech JIT Oncology Network, biopharma companies can identify and enroll more patients, faster. Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process. By implementing a Just-In-Time (JIT) Research System, site activation and patient enrollment is achievable within 14 days for pre-registered locations with pre-qualified patients.

Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit or follow us on Twitter (@CarisLS).

Investor Inquiries:
Argot Partners

Media Contact:
Lindsey Bailys
GCI Health

View original content to download multimedia:

SOURCE Caris Life Sciences